Advertisement

Tumor Biology

, Volume 35, Issue 12, pp 12519–12523 | Cite as

RETRACTED ARTICLE: Association of androgen receptor exon 1 CAG repeat length with risk of hepatocellular carcinoma: a case–control study

  • Kainan Li
  • Chen Zhong
  • Jun Wang
  • Baocheng Wang
  • Jun He
  • Jingwang Bi
Research Article

Abstract

Epidemiologic and biological data suggest a role for androgens and perhaps their receptor in hepatocellular carcinoma (HCC) development. However, few studies evaluated an association between HCC risk and androgen receptor (AR) cytosine, adenine, guanine (CAG) repeat length. To examine whether the relationship between the AR CAG repeats and HCC risk was also evident in Chinese, we conducted this large population-based, case–control study of 2,000 pathologically confirmed HCC patients and 2,000 frequency-matched controls. Two different approaches for AR CAG repeat length (analyses with continuous and categorized polymorphism variables) were conducted in the statistical analyses. For AR CAG longer allele (CAG_L), we found that subjects with longer AR CAG_L repeats had a decreased risk of developing HCC (OR = 0.87 for per CAG_A increase, 95 % CI 0.82–0.96, P = 5.33 × 10−4). Compared to those with the shorter (<23) CAG_L repeat length, subjects in the category of longer (≥23) CAG_L repeats had a significant 20 % decreased HCC risk (OR = 0.80, 95 % CI 0.71–0.91, P = 6.16 × 10−4). These findings suggest that androgen signaling underlies the development of HCC.

Keywords

Hepatocellular carcinoma Androgen receptor CAG Repeat length 

Notes

Acknowledgments

We thank all the staff who were involved in the subject recruitment, telephone interviews, sample preparation, and laboratory assays for their hard works.

Conflicts of interest

None

References

  1. 1.
    Mourad A, Deuffic-Burban S, Ganne-Carrie N, Renaut-Vantroys T, Rosa I, Bouvier AM, et al. Hepatocellular carcinoma screening in patients with compensated hepatitis C virus (HCV)-related cirrhosis aware of their HCV status improves survival: a modeling approach. Hepatology. 2014;59:1471–81.CrossRefPubMedGoogle Scholar
  2. 2.
    Deng Y, Li M, Wang J, Xie L, Li T, He Y, Lu Q, Li R, Tan A, Qin X, Li S: Susceptibility to hepatocellular carcinoma in the Chinese population-associations with interleukin-6 receptor polymorphism. Tumour Biol 2014Google Scholar
  3. 3.
    Long XD, Zhao D, Wang C, Huang XY, Yao JG, Ma Y, et al. Genetic polymorphisms in DNA repair genes XRCC4 and XRCC5 and aflatoxin B1-related hepatocellular carcinoma. Epidemiology. 2013;24:671–81.CrossRefPubMedGoogle Scholar
  4. 4.
    Song P. Standardizing management of hepatocellular carcinoma in China: devising evidence-based clinical practice guidelines. Biosci Trends. 2013;7:250–2.PubMedGoogle Scholar
  5. 5.
    Zheng J, Li C, Wu X, Yang Y, Hao M, Sheng S, et al. Astrocyte elevated gene-1 is a novel biomarker of epithelial-mesenchymal transition and progression of hepatocellular carcinoma in two China regions. Tumour Biol. 2014;35:2265–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Song P, Gao J, Inagaki Y, Kokudo N, Hasegawa K, Sugawara Y, et al. Biomarkers: evaluation of screening for and early diagnosis of hepatocellular carcinoma in Japan and China. Liver Cancer. 2013;2:31–9.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Wu J, Zhang W, Xu A, Zhang L, Yan T, Li Z, et al. Association of epidermal growth factor and epidermal growth factor receptor polymorphisms with the risk of hepatitis B virus-related hepatocellular carcinoma in the population of North China. Genet Test Mol Biomarkers. 2013;17:595–600.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Naveed M, Waljee AK, Singal AG: Predictive models for hepatocellular carcinoma. Gastroenterology 2014.Google Scholar
  9. 9.
    Yeh SH, Chang CF, Shau WY, Chen YW, Hsu HC, Lee PH, et al. Dominance of functional androgen receptor allele with longer cag repeat in hepatitis B virus-related female hepatocarcinogenesis. Cancer Res. 2002;62:4346–51.PubMedGoogle Scholar
  10. 10.
    Toh YC. Effect of neonatal castration on liver tumor induction by n-2-fluorenylacetamide in suckling balb/c mice. Carcinogenesis. 1981;2:1219–21.CrossRefPubMedGoogle Scholar
  11. 11.
    Firminger HI, Reuber MD. Influence of adrenocortical, androgenic, and anabolic hormones on the development of carcinoma and cirrhosis of the liver in a x c rats fed N-2-fluorenyldicetamide. J Natl Cancer Inst. 1961;27:559–95.PubMedGoogle Scholar
  12. 12.
    Granata OM, Cocciadifero L, Campisi I, Miceli V, Montalto G, Polito LM, et al. Androgen metabolism and biotransformation in nontumoral and malignant human liver tissues and cells. J Steroid Biochem Mol Biol. 2009;113:290–5.CrossRefPubMedGoogle Scholar
  13. 13.
    Liang L, Lu M, Huang J. Androgen receptor in hepatocellular carcinoma and the surrounding liver tissues in China. Zhonghua Zhong Liu Za Zhi. 1996;18:214–7.PubMedGoogle Scholar
  14. 14.
    Abdelgadir SE, Connolly PB, Resko JA. Androgen binding in peripheral tissues of fetal rhesus macaques: effects of androgen metabolism in liver. J Steroid Biochem Mol Biol. 1990;37:545–51.CrossRefPubMedGoogle Scholar
  15. 15.
    Davies HR, Hughes IA, Patterson MN. Genetic counselling in complete androgen insensitivity syndrome: trinucleotide repeat polymorphisms, single-strand conformation polymorphism and direct detection of two novel mutations in the androgen receptor gene. Clin Endocrinol (Oxf). 1995;43:69–77.CrossRefGoogle Scholar
  16. 16.
    Sleddens HF, Oostra BA, Brinkmann AO, Trapman J. Trinucleotide (ggn) repeat polymorphism in the human androgen receptor (AR) gene. Hum Mol Genet. 1993;2:493.CrossRefPubMedGoogle Scholar
  17. 17.
    Sleddens HF, Oostra BA, Brinkmann AO, Trapman J. Trinucleotide repeat polymorphism in the androgen receptor gene (AR). Nucleic Acids Res. 1992;20:1427.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Schildkraut JM, Murphy SK, Palmieri RT, Iversen E, Moorman PG, Huang Z, et al. Trinucleotide repeat polymorphisms in the androgen receptor gene and risk of ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2007;16:473–80.CrossRefPubMedGoogle Scholar
  19. 19.
    Yu MW, Yang YC, Yang SY, Chang HC, Liaw YF, Lin SM, et al. Androgen receptor exon 1 cag repeat length and risk of hepatocellular carcinoma in women. Hepatology. 2002;36:156–63.CrossRefPubMedGoogle Scholar
  20. 20.
    Yu MW, Cheng SW, Lin MW, Yang SY, Liaw YF, Chang HC, et al. Androgen-receptor gene cag repeats, plasma testosterone levels, and risk of hepatitis B-related hepatocellular carcinoma. J Natl Cancer Inst. 2000;92:2023–8.CrossRefPubMedGoogle Scholar
  21. 21.
    Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001;94:153–6.CrossRefPubMedGoogle Scholar
  22. 22.
    Chang C, Lee SO, Yeh S, Chang TM. Androgen receptor (AR) differential roles in hormone-related tumors including prostate, bladder, kidney, lung, breast and liver. Oncogene. 2014;33:3225–34.CrossRefPubMedGoogle Scholar
  23. 23.
    Gao B, Jiang L, Kunos G. Transcriptional regulation of alpha(1b) adrenergic receptors (alpha(1b)AR) by nuclear factor 1 (nf1): a decline in the concentration of nf1 correlates with the downregulation of alpha(1b)AR gene expression in regenerating liver. Mol Cell Biol. 1996;16:5997–6008.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Langner A, Nerlich C, Grahlmann D. Biotransformation of the trapidil (Rocornal) derivative AR 12,463 by the isolated, perfused rat liver and rat hepatocyte suspension cultures. Die Pharmazie. 1990;45:636.PubMedGoogle Scholar
  25. 25.
    Clark PE, Irvine RA, Coetzee GA. The androgen receptor cag repeat and prostate cancer risk. Methods Mol Med. 2003;81:255–66.PubMedGoogle Scholar
  26. 26.
    Hsing AW, Gao YT, Wu G, Wang X, Deng J, Chen YL, et al. Polymorphic cag and ggn repeat lengths in the androgen receptor gene and prostate cancer risk: a population-based case-control study in China. Cancer Res. 2000;60:5111–6.PubMedGoogle Scholar
  27. 27.
    Yeh SH, Chiu CM, Chen CL, Lu SF, Hsu HC, Chen DS, et al. Somatic mutations at the trinucleotide repeats of androgen receptor gene in male hepatocellular carcinoma. Int J Cancer. 2007;120:1610–7.CrossRefPubMedGoogle Scholar
  28. 28.
    Ferro P, Catalano MG, Dell’Eva R, Fortunati N, Pfeffer U. The androgen receptor cag repeat: a modifier of carcinogenesis? Mol Cell Endocrinol. 2002;193:109–20.CrossRefPubMedGoogle Scholar
  29. 29.
    Chamberlain NL, Driver ED, Miesfeld RL. The length and location of cag trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res. 1994;22:3181–6.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Kainan Li
    • 1
  • Chen Zhong
    • 1
  • Jun Wang
    • 1
  • Baocheng Wang
    • 1
  • Jun He
    • 2
  • Jingwang Bi
    • 1
  1. 1.Department of OncologyGeneral Hospital of Jinan Military RegionJinanPeople’s Republic of China
  2. 2.Department of Emergency MedicineGeneral Hospital of Jinan Military RegionJinanPeople’s Republic of China

Personalised recommendations